Q3 2024 · 13F-HR
Sarissa Capital Management LPholdings as filed
Filed 2024-11-14 · accession 0000899140-24-001252
$402.3M
Reported value
10
Positions
2024-09-30
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 45781M101 | INVA | INNOVIVA INC | $140.5M | 34.9% | 7,277,000 | Common | SOLE |
| 46333X108 | IRWD | IRONWOOD PHARMACEUTICALS INC | $67.5M | 16.8% | 16,390,000 | Common | SOLE |
| 375558103 | GILD | GILEAD SCIENCES INC | $64.0M | 15.9% | 763,333 | Common | SOLE |
| 23282W605 | CYTK | CYTOKINETICS INC | $58.6M | 14.6% | 1,110,000 | Common | SOLE |
| 64125C109 | NBIX | NEUROCRINE BIOSCIENCES INC | $47.3M | 11.8% | 410,483 | Common | SOLE |
| 023111206 | — | AMARIN CORP PLC | $15.6M | 3.87% | 24,850,623 | Common | SOLE |
| 09062X103 | BIIB | BIOGEN INC | $5.2M | 1.30% | 26,950 | Common | SOLE |
| 516544103 | LNTH | LANTHEUS HLDGS INC | $2.9M | 0.71% | 26,000 | Common | SOLE |
| 929033108 | — | VOR BIOPHARMA INC | $432,600 | 0.11% | 618,000 | Common | SOLE |
| 75915K309 | RGLS | REGULUS THERAPEUTICS INC | $290,737 | 0.07% | 185,183 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.